AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Cost of Revenue

Last Annual Value

20.42M

3-Year CAGR

6%

5-Year CAGR

8%

10-Year CAGR

31%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Cost of Revenue

SPRY · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
20.42M
N/A149.1%N/A 
363.00K
N/AN/A-40.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
245.00K
-82.3%-61.5%N/A
57.00K
-59.4%N/A6.3%
0.00
N/AN/AN/A
418.00K
N/A-10.6%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
5.72M
N/AN/AN/A
546.00K
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07